Key result
ACE inhibitors and certain ARBs, particularly telmisartan via PPARgamma activation, may improve insulin sensitivity and decrease the risk for type 2 diabetes.
Why the study?
Do ACE inhibitors and ARBs improve insulin sensitivity and decrease the risk for type 2 diabetes through mechanisms beyond the renin-angiotensin system?
Design
Review
Authors
Loading...
May support metabolic benefits of ACEIs and telmisartan beyond RAS blockade; leaves open confirmation in prospective diabetes prevention trials.
Do ACE inhibitors and ARBs improve insulin sensitivity and decrease the risk for type 2 diabetes through mechanisms beyond the renin-angiotensin system?
ACE inhibitors and specific ARBs like telmisartan may offer antidiabetic benefits through mechanisms independent of the renin-angiotensin system, such as PPARgamma activation.
Kurtz et al. (2004) conducted a review in Type 2 diabetes, hypertension, and metabolic syndrome. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), specifically telmisartan was evaluated. ACE inhibitors and certain ARBs, particularly telmisartan via PPARgamma activation, may improve insulin sensitivity and decrease the risk for type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: